|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113.04 EUR | -0.18% |
|
-1.22% | +6.98% |
| 30/07 | Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials | RE |
| 28/07 | Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial | MT |
| Market Cap | 16TCr 14TCr 13TCr 12TCr 23TCr 15,43300Cr 23TCr 1,54200Cr 61TCr 7,68300Cr 61TCr 59TCr 25,76200Cr | P/E 2026 * |
-46.9x | P/E 2027 * | 16.5x |
|---|---|---|---|---|---|
| Enterprise Value | 17TCr 15TCr 14TCr 13TCr 24TCr 16,34900Cr 24TCr 1,63300Cr 64TCr 8,13900Cr 64TCr 63TCr 27,29200Cr | EV / Sales 2026 * |
5.63x | EV / Sales 2027 * | 5.01x |
| Free-Float |
99.88% | Yield 2026 * |
2.53% | Yield 2027 * | 2.62% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | -0.18% | ||
| 1 week | -1.22% | ||
| 1 month | +1.97% | ||
| 3 months | +3.08% | ||
| 6 months | -4.38% | ||
| Current year | +6.98% |
| 1 week | 113.04 |  | 117.92 |
| 1 month | 110.42 | | 121.2 |
| Current year | 100.42 | | 132 |
| 1 year | 93.42 | | 132 |
| 3 years | 57.58 | | 132 |
| 5 years | 52.23 | | 132 |
| 10 years | 46.23 | | 132 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | -1.22% | - | - | 16TCr | |
| -0.53% | -3.95% | +55.23% | +152.74% | 1,02400Cr | |
| +0.21% | -2.68% | +55.61% | +53.02% | 62TCr | |
| -2.51% | -3.25% | +32.76% | +67.76% | 44TCr | |
| +0.06% | -0.42% | +37.53% | +30.67% | 35TCr | |
| -0.14% | -0.24% | +34.41% | +39.01% | 30TCr | |
| -0.69% | -0.30% | +11.55% | +12.93% | 26TCr | |
| -7.37% | -4.40% | -2.54% | -43.87% | 21TCr | |
| -0.64% | +2.43% | +30.52% | +64.49% | 21TCr | |
| +0.40% | +1.92% | +7.39% | -30.64% | 14TCr | |
| Average | -1.14% | -1.32% | +29.16% | +38.46% | 39.5TCr | |
| Weighted average by Cap. | -0.91% | -1.99% | +39.02% | +68.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.04TCr 2.64TCr 2.46TCr 2.26TCr 4.27TCr 2,90400Cr 4.33TCr 29TCr 11TCr 1,44600Cr 11TCr 11TCr 4,84800Cr | 3.23TCr 2.81TCr 2.61TCr 2.4TCr 4.53TCr 3,08300Cr 4.6TCr 31TCr 12TCr 1,53500Cr 12TCr 12TCr 5,14700Cr |
| Net income | -339.07Cr -294.75Cr -274.35Cr -251.89Cr -475.67Cr -32TCr -483.04Cr -3.23TCr -1.27TCr -16TCr -1.27TCr -1.25TCr -54TCr | 977.91Cr 850.1Cr 791.26Cr 726.47Cr 1.37TCr 93TCr 1.39TCr 9.33TCr 3.66TCr 46TCr 3.67TCr 3.59TCr 1,55800Cr |
| Net Debt | 959.75Cr 834.31Cr 776.56Cr 712.98Cr 1.35TCr 92TCr 1.37TCr 9.15TCr 3.59TCr 46TCr 3.6TCr 3.53TCr 1,52900Cr | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/26/31 | €113.04 | -0.18% | 700 |
| 30/26/30 | €113.24 | -3.67% | 125 |
| 29/26/29 | €117.56 | -0.25% | 30 |
| 28/26/28 | €117.86 | +2.49% | 90 |
| 27/26/27 | €115.00 | +0.49% | 175 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GIS Stock
Select your edition
All financial news and data tailored to specific country editions
